0SZI Stock Overview
A biopharmaceutical company, develops products to defeat serious illness. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Corbus Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.12 |
| 52 Week High | US$61.81 |
| 52 Week Low | US$6.06 |
| Beta | 2.63 |
| 1 Month Change | -25.00% |
| 3 Month Change | -53.09% |
| 1 Year Change | -83.88% |
| 3 Year Change | -56.59% |
| 5 Year Change | n/a |
| Change since IPO | -96.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0SZI | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -6.5% | 4.6% | 1.9% |
| 1Y | -83.9% | -7.9% | 9.4% |
Return vs Industry: 0SZI underperformed the UK Biotechs industry which returned -7.9% over the past year.
Return vs Market: 0SZI underperformed the UK Market which returned 9.4% over the past year.
Price Volatility
| 0SZI volatility | |
|---|---|
| 0SZI Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0SZI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0SZI's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 28 | Yuval Cohen | www.corbuspharma.com |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
Corbus Pharmaceuticals Holdings, Inc. Fundamentals Summary
| 0SZI fundamental statistics | |
|---|---|
| Market cap | US$73.76m |
| Earnings (TTM) | -US$40.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs 0SZI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0SZI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$32.22m |
| Gross Profit | -US$32.22m |
| Other Expenses | US$7.99m |
| Earnings | -US$40.21m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0SZI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/20 07:56 |
| End of Day Share Price | 2025/03/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Corbus Pharmaceuticals Holdings, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| George Zavoico | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |
| Kumaraguru Raja | Brookline Capital Markets |